Previous close | 107.43 |
Open | 107.00 |
Bid | 109.37 x 100 |
Ask | 109.57 x 100 |
Day's range | 106.73 - 110.82 |
52-week range | 106.61 - 146.70 |
Volume | |
Avg. volume | 607,512 |
Market cap | 6.824B |
Beta (5Y monthly) | 0.61 |
PE ratio (TTM) | 17.94 |
EPS (TTM) | 6.10 |
Earnings date | 01 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 188.35 |
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago. Presentations include data from trials of zanidatamab, Zepzelca® (lurbinectedin), and Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn). A poster featuring the study design for the JZP898 Phase 1 trial in progress will also be presented.
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.